May Patients Receiving GLP-1 Agonists Be at Lower Risk of Prostate Cancer Aggressiveness and Progression?

IF 4.5 2区医学 Q1 ONCOLOGY

Cancers Pub Date : 2025-05-06 DOI:10.3390/cancers17091576

Julia Drewa, Katarzyna Lazar-Juszczak, Jan Adamowicz, Kajetan Juszczak

{"title":"May Patients Receiving GLP-1 Agonists Be at Lower Risk of Prostate Cancer Aggressiveness and Progression?","authors":"Julia Drewa, Katarzyna Lazar-Juszczak, Jan Adamowicz, Kajetan Juszczak","doi":"10.3390/cancers17091576","DOIUrl":null,"url":null,"abstract":"Introduction: GLP-1 receptor agonists are valuable therapeutic agents for managing obesity and type 2 diabetes. The link between prostate cancer and obesity was described. The modulation of incretin hormone-dependent pathways may decrease the prostate cancer aggressiveness and progression.Objectives: The purpose of this study was to review and summarize the literature on the role of GLP-1 agonists in prostate cancer.Material & methods: We performed a scoping literature review of PubMed from January 2002 to February 2025. Search terms included \"glucagon-peptide like 1\", \"incretin hormone\", \"GLP-1 receptor agonist\", and \"prostate cancer\". Secondary search involved reference lists of eligible articles. The key criterion was to identify studies that included GLP-1 receptor, incretin hormones, GLP-1 receptor agonists, and their role in prostate cancer development.Results: 77 publications were selected for inclusion in this review. The studies contained in publications allowed us to summarize the data on the role of GLP-1 receptor and it's agonists in prostate cancer biology and development. The following review aims to discuss and provide information about the role of incretin hormones in prostate cancer pathogenesis and its clinical implication in patients with prostate cancer.Conclusion: Incretin hormone-dependent pathways play an important role in prostate cancer pathogenesis. Moreover, GLP-1 receptor agonists seems to be a promising therapeutical agents when it comes to finding new therapies in patients with more aggressive and/or advanced stages of prostate cancer.","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071316/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17091576","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: GLP-1 receptor agonists are valuable therapeutic agents for managing obesity and type 2 diabetes. The link between prostate cancer and obesity was described. The modulation of incretin hormone-dependent pathways may decrease the prostate cancer aggressiveness and progression.

Objectives: The purpose of this study was to review and summarize the literature on the role of GLP-1 agonists in prostate cancer.

Material & methods: We performed a scoping literature review of PubMed from January 2002 to February 2025. Search terms included "glucagon-peptide like 1", "incretin hormone", "GLP-1 receptor agonist", and "prostate cancer". Secondary search involved reference lists of eligible articles. The key criterion was to identify studies that included GLP-1 receptor, incretin hormones, GLP-1 receptor agonists, and their role in prostate cancer development.

Results: 77 publications were selected for inclusion in this review. The studies contained in publications allowed us to summarize the data on the role of GLP-1 receptor and it's agonists in prostate cancer biology and development. The following review aims to discuss and provide information about the role of incretin hormones in prostate cancer pathogenesis and its clinical implication in patients with prostate cancer.

Conclusion: Incretin hormone-dependent pathways play an important role in prostate cancer pathogenesis. Moreover, GLP-1 receptor agonists seems to be a promising therapeutical agents when it comes to finding new therapies in patients with more aggressive and/or advanced stages of prostate cancer.

查看原文本刊更多论文

接受GLP-1激动剂治疗的患者是否具有较低的前列腺癌侵袭性和进展风险？

简介：GLP-1受体激动剂是治疗肥胖和2型糖尿病的宝贵药物。描述了前列腺癌和肥胖之间的联系。调节肠促胰岛素激素依赖途径可能降低前列腺癌的侵袭性和进展。目的：本研究的目的是回顾和总结GLP-1激动剂在前列腺癌中的作用。材料与方法：我们对PubMed 2002年1月至2025年2月的文献进行了范围综述。搜索词包括“胰高血糖素样肽1”、“肠促胰岛素激素”、“GLP-1受体激动剂”和“前列腺癌”。二次检索涉及符合条件的文章的参考文献列表。关键标准是确定包括GLP-1受体、肠促胰岛素激素、GLP-1受体激动剂及其在前列腺癌发展中的作用的研究。结果：77篇文献被纳入本综述。发表的研究使我们能够总结关于GLP-1受体及其激动剂在前列腺癌生物学和发展中的作用的数据。本文旨在探讨促肠促胰岛素激素在前列腺癌发病中的作用及其在前列腺癌患者中的临床意义。结论：肠促胰岛素激素依赖通路在前列腺癌发病中起重要作用。此外，GLP-1受体激动剂似乎是一种很有前途的治疗药物，当涉及到寻找新的治疗方法时，患者的侵袭性和/或晚期前列腺癌。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancers Medicine-Oncology

CiteScore

8.00

自引率

9.60%

发文量

5371

审稿时长

18.07 days

期刊介绍： Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.